本帖最后由 老马 于 2013-3-13 13:43 编辑 : C7 ` ~* U( k6 R) D8 X
* \) i) ?1 c4 U7 ]" a a/ s1 \7 n
健择(吉西他滨)+顺铂+阿瓦斯汀) P3 S" k$ y! p* {* l% n* S
Gemzar +Cisplatin + Avastin
0 I+ O5 y5 x' J% T& P: ~: a, zhttp://annonc.oxfordjournals.org/content/21/9/1804.full" X" j2 Z+ z: ]" @+ D' D+ N( v L
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
. R" g7 F& i' S7 A2 bPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 0 l3 ~2 w! L' Q6 H/ w
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. , }+ {0 L5 h; v! ]8 q* y
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 258)
7 Q* N3 g3 |- z7 @华为网盘附件:0 h& d; H" H5 m" z3 ?( Q( Q
【华为网盘】ava.JPG
. j# C3 n8 Z1 B$ }( I* K8 s7 f8 B |